Sensory NeuronopathyNEURONOSCORENCT07651540
Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study
A study testing Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies. in people with Sensory Neuronopathy, run by Centre Hospitalier Universitaire de Saint Etienne at 19 sites in 2 countries.
Trial summary
Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sensory Neuronopathy
- What is being tested?
- Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 19 sitesin 2 countries
- Study dates
- 6 Jul 2026to 25 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient affiliated with or beneficiary of a social security system
- Patient having received appropriate study information
- Adult patient ≥18 years old, male or female
- Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria
- SN with one of the following etiologies:
- Paraneoplastic SN with anti-Hu or anti-CV2/CRMP5 antibodies SN associated with Sjögren's syndrome, systemic lupus erythematosus, or primary biliary cholangitis Platinum-salt-induced SN SN caused by CANVAS syndrome
Who cannot join
- Patient unable to understand or read French
- Patient refusal to participate
- Patient known to have another neuropathy phenotype and/or etiology that could significantly influence clinical scales and electrophysiological parameters, including:
- Diabetes mellitus
- Significant alcohol consumption
- Severe chronic kidney disease (GFR <30 ml/min)
Show all 10Show fewer
- Vitamin B12 and/or vitamin E deficiency
- Vitamin B6 excess
- Chemotherapy other than platinum salts
- HIV infection
Trial locations and contacts
19 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
19 sites in 2 countries
France16 sites, 16 recruiting
- Not yet recruiting
Chu D Angers
Angers
CASSEREAU PH JULIEN, +33 2 41 35 62 64, jucassereau@chu-angers.fr
- Not yet recruiting
Chu de Clermont Ferrand
Clermont-Ferrand
PONCET- MAGEMONT DR Louis, +33 4 73 752 202, lponcet-megemnt@chu-clermontferrand.fr
- Not yet recruiting
Chu de Grenoble
Grenoble
MALLARET DR MARTIAL, +33 4 76 76 54 49, mmallaret1@chu-grenoble.fr
- Not yet recruiting
Chu de Lille
Lille
TARD DR CELINE, +33 3 20 44 41 45, celine.tard@chu-lillle.fr
- Not yet recruiting
Chu de Limoges
Limoges
MAGY PHD Laurent, +33 5 55 05 65 61, laurent.magy@unilim.fr
- Not yet recruiting
Hospices Civils de Lyon
Lyon
BOUHOUR DR Francoise, +33 4 72 11 80 63, francoise.bouhour@chu-lyon.fr
- Not yet recruiting
Hopitaux Universitaire de Marseille
Marseille
DELMONT DR Emilien, +33 4 91 38 65 79, emilien.delmont@ap-hm.fr
- Not yet recruiting
Chu de Nancy
Nancy
MICHAUD DR MAUD, +33 3 83 85 94 88, m.michaud@chru-nancy.fr
- Not yet recruiting
Chu de Nantes
Nantes
PEREON PHD Yann, +33 240 083 704, Yann.Pereon@univ-nantes.fr
- Not yet recruiting
Chu de Nice
Nice
PUMA DR ANGELA, +33 4 92 03 90 73, puma.ar@chu-nice.fr
- Not yet recruiting
Hopital, Bicetre
Paris
ECHANIZ-LAGUNA PHD ANDONI, +33 1 45 21 31 59, andoni.echaniz-laguna@aphp.fr
- Recruiting
Chu de Saint-Etienne
Saint-Etienne, 42055
JEAN-PHILIPPE CAMDESSANCHE, PHD, (4)77120559, j.philippe.camdessanche@chu-st-etienne.fr
- Not yet recruiting
CHU St Etienne
Saint-Etienne
LOSER Dr Valentin, 0477127805, valentin.loser@chu-st-etienne.fr
- Not yet recruiting
Chu de La Reunion
Saint-Pierre
CHOUMERT DR ARIANE, +262 262 35 91 66, ariane.choumert@chu-reunion.fr
- Not yet recruiting
Hopitaux Universitaire de Strasbourg
Strasbourg
CHANSON DR JEAN BAPTISTE, +33 3 88 12 85 60, jean-baptiste.chanson@chru-strasbourg.fr
- Not yet recruiting
Chu de Toulouse
Toulouse
CINTAS DR PASCAL, +33 5 61 77 94 40, cintas.p@chu-toulouse.fr
Switzerland3 sites, 3 recruiting
- Not yet recruiting
Hopitaux Universitaire de Geneve
Geneva
LASCANO DR AGUSTINE, +41 22 372 83 58, Agustina.Lascano@hug.ch
- Not yet recruiting
Chuv Centre Hospitalier Vaudois
Lausanne
THEAUDIN PHD MARINE, 0041(0)21 314 81 26, marie.theaudin@chuv.ch
- Not yet recruiting
Hopital de Sion
Sion
ALVAREZ DR VINCENT, +41 27 603 40 00, vincent.alvarez@hopitalvs.ch
About this study
Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. The functional prognosis of patients with SN is generally poor: in a recent study, two-thirds of patients had a modified Rankin Scale (mRS) score ≥3 and nearly half had an mRS ≥4.
The absence of reliable biomarkers in neuropathies justifies the use of clinical scales as indicators of disease severity, disability, and treatment response. However, none of the currently available "general neuropathy" scales have been specifically designed or validated for SN. The only scale developed specifically for SN is the SEARS (Sensory Ataxia Rating Scale), proposed in 2019, but it has not been widely used nor validated in large populations.
As a result, the absence of a clinical scale specifically designed for patients with SN makes longitudinal follow-up more challenging, particularly when assessing the response to immunomodulatory or immunosuppressive treatments when these therapies are indicated.
- Conditions
- Sensory Neuronopathy
- Being tested
- Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies.
- Keywords
- neurology, specific scale, rare neuropathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies.Other
After patient consent, three follow-up visits (T0, T6, T12) will be scheduled. Some information will already be collected at baseline (demographics, medical history, comorbidities). Three visits will be conducted: (T0), Follow-up at 6 months (T6), Follow-up at 12 months (T12)
At each visit the following will be assessed:
Clinical scales: mISS, SEARS, CADT, SARA, ONLS, I-RODS, 9-Hole Peg Test, Timed Up and Go test, mRS, Quantified Rydel tuning fork test, Visual Analog Scale (VAS) ENMG including sensory nerve action potentials of the radial and sural nerves (antidromic recording
| Study group | Role | What they receive |
|---|---|---|
| Group experimental | Experimental | Not described Receives: Other: Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Clinical Global Impression of Change (CGI-C) and The Patient Global Impression of Change (PGI-C).
Global Impression of change measure evaluating overall change in clinical status compared with baseline.
Measured: 6 months and 12 months
Secondary outcomes (12)
miSS Score change
Change in mISS score from baseline.
Measured: 6 months and 12 months
SEARS change
Change in SEARS score from baseline.
Measured: 6 months, 12 months
CADT change
Change in CADT score from baseline.
Measured: 6 months and 12 months
SARA change
Change in SARA score from baseline.
Measured: 6 months and 12 months
ONLS change
Change in ONLS score from baseline.
Measured: 6 months and 12 months
I-RODS change
Change in I-RODS score from baseline.
Measured: 6 months and 12 months
9-Hole Peg Test change
Change in 9-Hole Peg Test score from baseline.
Measured: 6 months and 12 months
Timed Up and Go test change
Change in Timed Up and Go test from baseline
Measured: 6 months and 12 months
Modified Rankin Scale change
Change in Modified Rankin Scale from baseline
Measured: 6 months and 12 months
Quantified Rydel tuning fork test change
Change in Quantified Rydel tuning fork test from baseline
Measured: 6 months and 12 months
Visual Analog Scale change
Change in Visual Analog scale frome baseline
Measured: 6 months and 12 months
Electroneuromyography
Change in Electroneuromyography from baseline
Measured: 6 months and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jun 2026
- Study start6 Jul 2026
- Primary completion25 Jun 2028 (estimated)
- Study completion25 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sensory NeuronopathyStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de Saint EtienneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07651540
- Sponsor's protocol ID
- 26CH090
- Other IDs
- 2026-A00695-46
- Acronym
- NEURONOSCORE
- Status last verified
- Jun 2026
- First submitted
- 8 Jun 2026
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study
- ClinicalTrials.gov ID
- NCT07651540
- Acronym / sponsor ID
- NEURONOSCORE / 26CH090
- Conditions
- Sensory Neuronopathy
- Keywords
- neurology, specific scale, rare neuropathy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de Saint EtienneUniversity, hospital or other
- Study start
- 6 Jul 2026 (actual)
- Primary completion
- 25 Jun 2028 (estimated)
- Study completion
- 25 Jun 2028 (estimated)
- First posted
- 16 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. The functional prognosis of patients with SN is generally poor: in a recent study, two-thirds of patients had a modified Rankin Scale (mRS) score ≥3 and nearly half had an mRS ≥4.
The absence of reliable biomarkers in neuropathies justifies the use of clinical scales as indicators of disease severity, disability, and treatment response. However, none of the currently available "general neuropathy" scales have been specifically designed or validated for SN. The only scale developed specifically for SN is the SEARS (Sensory Ataxia Rating Scale), proposed in 2019, but it has not been widely used nor validated in large populations.
As a result, the absence of a clinical scale specifically designed for patients with SN makes longitudinal follow-up more challenging, particularly when assessing the response to immunomodulatory or immunosuppressive treatments when these therapies are indicated.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group experimental | Experimental | Other: Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patient affiliated with or beneficiary of a social security system
- Patient having received appropriate study information
- Adult patient ≥18 years old, male or female
- Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria
- SN with one of the following etiologies:
Key exclusion criteria (10 listed)
- Patient unable to understand or read French
- Patient refusal to participate
- Patient known to have another neuropathy phenotype and/or etiology that could significantly influence clinical scales and electrophysiological parameters, including:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies.After patient consent, three follow-up visits (T0, T6, T12) will be scheduled. Some information will already be collected at baseline (demographics, medical history, comorbidities). Three visits will be conducted: (T0), Follow-up at 6 months (T6), Follow-up at 12 months (T12) At each visit the following will be assessed: Clinical scales: mISS, SEARS, CADT, SARA, ONLS, I-RODS, 9-Hole Peg Test, Timed Up and Go test, mRS, Quantified Rydel tuning fork test, Visual Analog Scale (VAS) ENMG including sensory nerve action potentials of the radial and sural nerves (antidromic recording | Other | Group experimental |
Primary outcome
The Clinical Global Impression of Change (CGI-C) and The Patient Global Impression of Change (PGI-C).
Time frame: 6 months and 12 months
Global Impression of change measure evaluating overall change in clinical status compared with baseline.
12 secondary outcomes
miSS Score change
Time frame: 6 months and 12 months
SEARS change
Time frame: 6 months, 12 months
CADT change
Time frame: 6 months and 12 months
SARA change
Time frame: 6 months and 12 months
ONLS change
Time frame: 6 months and 12 months
I-RODS change
Time frame: 6 months and 12 months
9-Hole Peg Test change
Time frame: 6 months and 12 months
Timed Up and Go test change
Time frame: 6 months and 12 months
Modified Rankin Scale change
Time frame: 6 months and 12 months
Quantified Rydel tuning fork test change
Time frame: 6 months and 12 months
Visual Analog Scale change
Time frame: 6 months and 12 months
Electroneuromyography
Time frame: 6 months and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Sensory Neuronopathy
Not yet recruitingObservational study
Nerve Ultrasound in Acquired and Genetic Sensory Neuronopathies
Sensory Neuronopathy
RecruitingPhase 2
Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy
Paraneoplastic Sensory Neuronopathy
Not yet recruitingPhase 4
IVIG in Painful Sensory Neuropathy
Sensory Neuropathy, Small Fiber Neuropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
19 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies. in people with Sensory Neuronopathy, run by Centre Hospitalier Universitaire de Saint Etienne at 19 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 19 sites in France, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jean philippe PHD CAMDESSANCHE (+33 4 77 12 05 59, j.philippe.camdessanche@chu-st-etienne.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Clinical Global Impression of Change (CGI-C) and The Patient Global Impression of Change (PGI-C). (time frame: 6 months and 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.